ROCHE HLDG - Dusseldorf Stock Exchang (RHO DU) stock market data APIs
€322.3175
-6.28(-1.9%)
as of October 17, 2025
Try our APIs with
free plan!
ROCHE HLDG - Dusseldorf Stock Exchang Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for RHO.DU.
Prev. Close
322.3175
Open
316.0363
High
322.3175
Low
314.8186
52 wk Range
235.2567-330.4
Market Cap
312 681 M
Dividends (Yield)
0.0415
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ROCHE HLDG - Dusseldorf Stock Exchang data using free add-ons & libraries
Get ROCHE HLDG - Dusseldorf Stock Exchang Fundamental Data
ROCHE HLDG - Dusseldorf Stock Exchang Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
Get ROCHE HLDG - Dusseldorf Stock Exchang End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ROCHE HLDG - Dusseldorf Stock Exchang News
New
Genentech’s Phase III evERA Data Showed Giredestrant Significantly Improved Progression-Free Survival in People With ER-Positive Advanced Breast Cancer
– Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, in a post-CDK inhibitor setting, compared with stand...
Roche’s phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer
F. Hoffmann-La Roche Ltd Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, in a post-CDK inhibitor settin...
Genentech Presents New Phase III Pivotal Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss
– Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving UME and may offer a potential new treatment option for patients – – Vision improvements were seen...
Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
F. Hoffmann-La Roche Ltd Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving UME and may offer a potential new treatment option for patients Vision improveme...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
